NASDAQ · FDMT
Healthcare · Biotechnology
$11.87
Down-$0.22 (-1.85%)
Updated Aug 13, 2026, 8:09 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
FDMT closed at $11.87 after 21 trading sessions, up 1.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $11.50 | $11.89 | $11.3447 | $11.87 | 430.3K |
| Aug 11, 2026 | $11.31 | $11.54 | $10.8014 | $11.47 | 453.67K |
| Aug 10, 2026 | $10.66 | $11.30 | $10.5404 | $11.14 | 940.94K |
| Aug 7, 2026 | $10.66 | $10.84 | $10.45 | $10.75 | 346.9K |
| Aug 6, 2026 | $10.21 | $10.69 | $10.21 | $10.55 | 297.34K |
| Aug 5, 2026 | $10.35 | $10.62 | $10.18 | $10.28 | 664.78K |
| Aug 4, 2026 | $10.35 | $10.4844 | $10.06 | $10.26 | 478.3K |
| Aug 3, 2026 | $10.17 | $10.33 | $9.66 | $10.09 | 463.65K |
| Jul 31, 2026 | $10.54 | $10.65 | $9.84 | $10.18 | 716.31K |
| Jul 30, 2026 | $9.79 | $10.15 | $9.73 | $10.07 | 539.92K |
| Jul 29, 2026 | $9.82 | $9.98 | $9.39 | $9.61 | 529.95K |
| Jul 28, 2026 | $10.28 | $10.37 | $9.50 | $9.85 | 628.85K |
| Jul 27, 2026 | $10.22 | $10.655 | $10.12 | $10.38 | 531.42K |
| Jul 24, 2026 | $10.38 | $10.46 | $9.905 | $10.07 | 682.43K |
| Jul 23, 2026 | $10.66 | $10.94 | $10.31 | $10.38 | 567.29K |
| Jul 22, 2026 | $11.20 | $11.43 | $10.91 | $10.96 | 717.18K |
| Jul 21, 2026 | $11.13 | $11.96 | $11.005 | $11.375 | 1.03M |
| Jul 20, 2026 | $10.88 | $11.50 | $10.88 | $11.09 | 821.6K |
| Jul 17, 2026 | $10.51 | $11.28 | $10.29 | $10.99 | 598.91K |
| Jul 16, 2026 | $11.37 | $11.6187 | $10.75 | $10.84 | 893.77K |
| Jul 15, 2026 | $11.63 | $11.755 | $11.255 | $11.68 | 419.76K |
The latest Smart Investors Daily articles mentioning FDMT.
FDMT research
Company profile and research snapshot.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | B. Riley Securities | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 20, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 19, 2026 | RBC Capital | Outperform | — |
| Mar 19, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 31, 2026
B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.
Benzinga · Jul 20, 2026
4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
Benzinga · Jul 20, 2026
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.
Benzinga · Jul 20, 2026
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FDMT.
